Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From FibroGen, Inc.
The FDA has almost 30 decision dates coming up before New Year’s Eve, including nearly a dozen novel agents.
The termination of a major idiopathic pulmonary fibrosis collaboration between Bridge Biotherapeutics and Boehringer Ingelheim is a blow to both companies in an increasingly competitive indication, but the Korean biotech says it's still committed to further development of the autotaxin inhibitor and will work out a future development plan.
Private Company Edition: Also, Medicxi’s new €200m fund will be reinvested in a portfolio of six life science companies and Silverback more than doubled its 2020 money with an $85m series C round.
HIF-PHI inhibitor failed to show non-inferiority to ESAs in the primary cardiovascular safety endpoint of a Phase III program for the treatment of anemia due to chronic kidney disease.
- Other Names / Subsidiaries
- FibroGen China Anemia Holdings Ltd.
- FibroGen (China) Medical Technology Development Co., Ltd.
- FibroGen Europe Oy
- FibroGen International (Cayman) Limited
- FibroGen International (Hong Kong) Limited
- Skin Sciences, Inc.